PMID- 33275238
OWN - NLM
STAT- MEDLINE
DCOM- 20210629
LR  - 20210629
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 22
DP  - 2020 Nov
TI  - Relationships between diabetic nephropathy and insulin resistance, inflammation, 
      Trx, Txnip, CysC and serum complement levels.
PG  - 11700-11706
LID - 23815 [pii]
LID - 10.26355/eurrev_202011_23815 [doi]
AB  - OBJECTIVE: To investigate the relationships between diabetic nephropathy (DN) and 
      insulin resistance, inflammation, thioredoxin (Trx), thioredoxin-interacting 
      protein (Txnip), Cystatin C (CysC) and serum complement levels. PATIENTS AND 
      METHODS: A total of 119 patients with type 2 diabetes mellitus (T2DM) treated in 
      the Endocrinology Department of our hospital from January 2017 to December 2017 
      were enrolled as the experiment group, while 30 healthy volunteers were selected 
      as the control group. The expression levels of inflammatory factors, Trx, Txnip, 
      CysC and serum complements in every subject were detected. In addition, the type 
      2 diabetic nephropathy rat model was established via high-fat diet and injection 
      of low-dose streptozotocin. Blood glucose, insulin resistance indexes and 
      24h-urinary albumin excretion were measured, and the histomorphological 
      characteristics of the kidney in animals were observed. RESULTS: In clinical 
      subjects, Trx level was notably lower in the simple DM group, early DN group and 
      clinical DN group in comparison with that in the control group. The levels of 
      Txnip and CysC in the simple DM group, early DN group and clinical DN group were 
      remarkably higher than those in the control group. Moreover, the expression 
      levels of TNF-alpha and IL-6 in the clinical DN group were significantly elevated 
      compared with those in the simple DM group and early DN group. In addition, C1q 
      expression in the clinical DN group was higher than that in the simple DM group 
      and early DN group. In model rats, HOMA-IR was distinctly higher in the DM group 
      and DN group than that in the control group. The ratio of kidney weight to body 
      weight (KW/BW) was evidently higher in the DN group in comparison with that in 
      the control group and DM group. CONCLUSIONS: Insulin resistance, inflammatory 
      factors, and levels of Trx, Txnip, CysC and serum complement C1q are related to 
      the progression of DM.
FAU - Xu, L-L
AU  - Xu LL
AD  - Department of Laboratory Medicine, The First People's Hospital of Yancheng City, 
      Yancheng, China. Guonaizhou@sina120.com.
FAU - Gao, W
AU  - Gao W
FAU - Chen, Z-M
AU  - Chen ZM
FAU - Shao, K-K
AU  - Shao KK
FAU - Wang, Y-G
AU  - Wang YG
FAU - -L Cui, L
AU  - -L Cui L
FAU - Guo, N-Z
AU  - Guo NZ
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Blood Glucose)
RN  - 0 (Carrier Proteins)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cystatin C)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (TXNIP protein, human)
RN  - 0 (TXNIP protein, rat)
RN  - 0 (Txn1 protein, rat)
RN  - 0 (VAC14 protein, human)
RN  - 52500-60-4 (Thioredoxins)
RN  - 5W494URQ81 (Streptozocin)
RN  - 80295-33-6 (Complement C1q)
SB  - IM
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Carrier Proteins/analysis
MH  - Cell Cycle Proteins/analysis
MH  - Complement C1q/analysis
MH  - Cystatin C/analysis
MH  - Diabetes Mellitus, Experimental/chemically induced/*pathology
MH  - Diabetes Mellitus, Type 2/chemically induced/*pathology
MH  - Diabetic Nephropathies/chemically induced/*pathology
MH  - Diet, High-Fat/adverse effects
MH  - Disease Models, Animal
MH  - Humans
MH  - Inflammation/chemically induced/*pathology
MH  - Insulin Resistance
MH  - Intracellular Signaling Peptides and Proteins/analysis
MH  - Male
MH  - Membrane Proteins/analysis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin/administration & dosage
MH  - Thioredoxins/analysis
EDAT- 2020/12/05 06:00
MHDA- 2021/06/30 06:00
CRDT- 2020/12/04 12:08
PHST- 2020/12/04 12:08 [entrez]
PHST- 2020/12/05 06:00 [pubmed]
PHST- 2021/06/30 06:00 [medline]
AID - 23815 [pii]
AID - 10.26355/eurrev_202011_23815 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Nov;24(22):11700-11706. doi: 
      10.26355/eurrev_202011_23815.